Dan Leonard
Stock Analyst
(3.61)
# 3,827
Out of 4,648 analysts
272
Total ratings
51.09%
Success rate
5.24%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $25 → $20 | $16.55 | +20.85% | 3 | Oct 30, 2024 | |
| DHR Danaher | Maintains: Buy | $309 → $305 | $246.62 | +23.67% | 16 | Oct 23, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $7 → $9 | $7.55 | +19.21% | 2 | Oct 18, 2024 | |
| MEDP Medpace Holdings | Downgrades: Neutral | $420 → $350 | $315.37 | +10.98% | 1 | Sep 27, 2024 | |
| CERT Certara | Upgrades: Buy | $16 | $10.16 | +57.52% | 9 | Sep 27, 2024 | |
| GH Guardant Health | Maintains: Buy | $32 → $40 | $23.35 | +71.31% | 8 | Aug 21, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $295 → $300 | $209.12 | +43.46% | 12 | Jul 23, 2024 | |
| BIO Bio-Rad Laboratories | Maintains: Buy | $420 → $385 | $369.91 | +4.08% | 19 | May 8, 2024 | |
| BIO.B Bio-Rad Laboratories | Maintains: Buy | $420 → $385 | $334.85 | +14.98% | 19 | May 8, 2024 | |
| RVTY Revvity | Downgrades: Neutral | $105 → $125 | $123.35 | +1.34% | 1 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $75.72 | +5.66% | 10 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $21.24 | +64.78% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $138.63 | +8.21% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $154.36 | +29.57% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $7.80 | +41.03% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $123.18 | -43.17% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $90 | $72.11 | +24.81% | 9 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $24 | $22.40 | +7.17% | 6 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $620 | $552.61 | +12.20% | 13 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $255 | $182.23 | +39.94% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $5.29 | +32.45% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $385.74 | -10.56% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $218.88 | +18.79% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $154.28 | -6.01% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $83.77 | +7.44% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $62 | $43.71 | +41.39% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $227.04 | +49.75% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $85 → $90 | $59.44 | +51.41% | 9 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $19.77 | +21.40% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,350 → $1,500 | $1,365.49 | +9.85% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $17.62 | +98.64% | 12 | Aug 14, 2019 |
10x Genomics
Oct 30, 2024
Maintains: Neutral
Price Target: $25 → $20
Current: $16.55
Upside: +20.85%
Danaher
Oct 23, 2024
Maintains: Buy
Price Target: $309 → $305
Current: $246.62
Upside: +23.67%
Cryoport
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $7.55
Upside: +19.21%
Medpace Holdings
Sep 27, 2024
Downgrades: Neutral
Price Target: $420 → $350
Current: $315.37
Upside: +10.98%
Certara
Sep 27, 2024
Upgrades: Buy
Price Target: $16
Current: $10.16
Upside: +57.52%
Guardant Health
Aug 21, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $23.35
Upside: +71.31%
IQVIA Holdings
Jul 23, 2024
Maintains: Buy
Price Target: $295 → $300
Current: $209.12
Upside: +43.46%
Bio-Rad Laboratories
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $369.91
Upside: +4.08%
Bio-Rad Laboratories
May 8, 2024
Maintains: Buy
Price Target: $420 → $385
Current: $334.85
Upside: +14.98%
Revvity
Jan 16, 2024
Downgrades: Neutral
Price Target: $105 → $125
Current: $123.35
Upside: +1.34%
Dec 7, 2023
Initiates: Buy
Price Target: $80
Current: $75.72
Upside: +5.66%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $21.24
Upside: +64.78%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $138.63
Upside: +8.21%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $154.36
Upside: +29.57%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $7.80
Upside: +41.03%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $123.18
Upside: -43.17%
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $72.11
Upside: +24.81%
Jul 31, 2023
Reiterates: Neutral
Price Target: $24
Current: $22.40
Upside: +7.17%
Jul 13, 2023
Upgrades: Outperform
Price Target: $620
Current: $552.61
Upside: +12.20%
May 12, 2023
Maintains: Outperform
Price Target: $260 → $255
Current: $182.23
Upside: +39.94%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $5.29
Upside: +32.45%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $385.74
Upside: -10.56%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $218.88
Upside: +18.79%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $154.28
Upside: -6.01%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $83.77
Upside: +7.44%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $43.71
Upside: +41.39%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $227.04
Upside: +49.75%
Nov 2, 2021
Maintains: Equal-Weight
Price Target: $85 → $90
Current: $59.44
Upside: +51.41%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $19.77
Upside: +21.40%
Jul 30, 2021
Maintains: Equal-Weight
Price Target: $1,350 → $1,500
Current: $1,365.49
Upside: +9.85%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $17.62
Upside: +98.64%